Dataset Information

Utilizing of quantitative proteomics to identify species-specific protein therapeutic target for treatment of leishmaniasis.

ABSTRACT: Identification of common Leishmania antigen proteins is important for practical purposes ranging from diagnostic to the development of a vaccine for the prevention of leishmaniasis. Moreover, we need to establish the potential drug targets that interrupt the replication and transmission of the pathogen to promote drug discovery. Therefore, the objective of this work was to provide the public proteome database which would be useful for the establishment of novel protein antigenicity for therapeutic purposes. This information would introduce the alternative protein targets for Leishmaniasis, allowing the development of therapeutic strategies for the disease.

INSTRUMENT(S):

ORGANISM(S): Leishmania Donovani Ld 2001

TISSUE(S): Cell Culture, Diploid Cell

DISEASE(S): Leishmaniasis

SUBMITTER: Sucheewin Krobthong

LAB HEAD: Kiattawee Choowongkomon

PROVIDER: PXD026304 | Pride | 2022-05-20

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

Items per page:

1 - 5 of 14

Publications

Utilizing Quantitative Proteomics to Identify Species-Specific Protein Therapeutic Targets for the Treatment of Leishmaniasis.

Krobthong Sucheewin S Yingchutrakul Yodying Y Samutrtai Pawitrabhorn P Hitakarun Atitaya A Siripattanapipong Suradej S Leelayoova Saovanee S Mungthin Mathirut M Choowongkomon Kiattawee K

ACS omega 20220404 15

Leishmaniasis is a tropical disease caused by Leishmania parasites, which are transmitted through the bites of infected sandflies. We focused on the emergence of leishmaniasis in Thailand caused by a species (Leishmania orientalis). Treatment by chemotherapy is not effective against L. orientalis. Hence, we intended to solve this issue using a proteomics approach to investigate protein profiles and in silico analysis for the identification of antigenic proteins from < ...[more]

PMID: 35474788

Similar Datasets

Project description:Most patients with triple negative breast cancer (TNBC) fail to respond to anti-PD1/PDL1 immunotherapy, indicating the necessity to explore immune checkpoint targets. B7H3 is a highly glycosylated protein. However, the mechanisms of B7H3 glycosylation regulation and whether the sugar moiety contributes to immunosuppression remain elusive. Here, we identify aberrant B7H3 glycosylation and found N-glycosylation of B7H3 at NXT motif sites are responsible for its protein stability and immunosuppression in TNBC tumors. Mechanistically, fucosyltransferase FUT8 catalyzes B7H3 core fucosylation at N-glycans to maintain its high expression. Knockdown of FUT8 rescues glycosylated B7H3-mediated immunosuppressive function in TNBC cells. Abnormal B7H3 glycosylation mediated by FUT8 overexpression could be physiologically significant and clinically relevant in TNBC patients. Notably, combination of core fucosylation inhibitor 2F-Fuc and anti-PDL1 results in enhanced therapeutic efficacy in B7H3-positive TNBC tumors. These suggest targeting FUT8-B7H3 axis can be a promising strategy for improving anti-tumor immune responses in TNBC patients. To obtain the direct evidence that B7H3 is N-glycosylated in TNBC cells, we analysed the peptides of purified human B7H3 protein from B7H3-WT re-expressed and B7H3-8NQ re-expressed MDA-MB-231 cell lines by Nanoscale liquid chromatography coupled to tandem MS (nano LC-MS/MS). The result showed that there were eight N-glycosylation sites (Asn positions 91, 104, 189, 215, 309, 322, 407, and 433) in B7H3-WT cells, but not in B7H3-8NQ cells, as determined by Asn to Asp conversion after PNGase F treatment. As B7H3 contains a nearly exact tandem duplication of the IgV-IgC domain, there were four pairs of N-glycosylation sites identified through identical peptide sequence, including N91 and N309, N104 and N322, N189 and N407, and N215 and N433, in each of the IgV-IgC domains. Together, the results indicate that B7H3 is exclusively N-glycosylated at these four pairs of glycosylation sites in TNBC cells.

			Action	DRS
	le1_01.raw	Raw
	le1_02.raw	Raw
	le1_03.raw	Raw
	le1_04.raw	Raw
	le2_01.raw	Raw